Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 61, Issue 1, 1996, Pages 94-96

  Currie, John L ^a,f   Blessing, John A ^b   Mcgehee, Ramon ^c   Soper, John T ^d   Berman, Michael ^e  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; ETOPOSIDE; HYDROXYUREA;

ABDOMINAL HYSTERECTOMY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; RECURRENT CANCER; UTERUS TUMOR;

EID: 0029872510     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0103     Document Type: Article

References (9)

1. Currie, J., Swinger, T., Dudzinski, M., Walton, L., and Fowler, W. Combination chemotherapy for patients with recurrent or advanced uterine sarcomas, Gynecol. Oncol. 20, 254 (1985).
2. Major, F. J., Blessing, J. A., Silverberg, S. G., Morrow, C. P., Creasman, W. T., Currie, J. L., Yordan, E., and Brady, M. F. Prognostic factors in early stage uterine sarcoma: A Gynecologic Oncology Group study, Cancer 71, 1702-1709 (1993).
3. Omura, G. A., Blessing, J. A., Major, F. J., Lifshitz, S., Mangan, C., Beecham, J., Park, R., and Silverberg, S. A randomized clinical trial of adjuvant Adriamycin in uterine sarcoma: A Gynecologic Oncology Group study, J. Clin. Oncol. 3, 1240-1245 (1985).
4. Hornback, N. B., Omura, G., and Major, F. J. Observations on the use of adjuvant radiation therapy in the treatment of stage I and II uterine sarcoma by the Gynecologic Oncology Group, Int. J. Radiat. Oncol. Biol. Phys. 12, 2121-2130 (1986).
5. Omura, G. A., Major, F. J., Blessing, J. A., Sedlacek, T. V., Thigpen, J. T., Creasman, W. T., and Zaino, R. J. A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcoma, Cancer 52, 626-632 (1983).
6. Thigpen, J. T., Blessing, J. A., and Orr, J. W. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus, Cancer Treat. Rep. 70, 271-274 (1986).
7. Piver, M. S., DeEulis, T. G., Lele, S. B., and Barlow, J. J. Cyclophosphamide, vincristine, Adriamycin, and dimethyl triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract, Gynecol. Oncol. 14, 319-323 (1982).
8. Hannigan, E. V., Freedman, R. S., Elder, K. W., and Rutledge, F. N. Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide, Gynecol. Oncol. 15, 224-229 (1983).
9. Sutton, G. P., Blessing, J. A., Rosenshein, N., Photopulos, G., and DiSaia, P. J. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group Study), Am. J. Obstet. Gynecol. 161, 309-312 (1989).